Authors disclosed final efficacy and safety details from the Phase I/II ARROW study of pralsetinib in patients with advanced RET fusion–positive non–small cell lung cancer. The update provides additional readout from the ongoing disclosure pathway tied to study publications and conference reporting. The ARROW program continues to be viewed as a key evidence source for pralsetinib’s performance in RET-driven NSCLC, where biomarker confirmation and treatment sequencing remain central to clinical decision-making. Finalizing the dataset can affect how clinicians evaluate response durability and safety across patient subgroups. Because the disclosure text in the provided feed is primarily administrative, the most actionable near-term impact is the availability of complete outcome reporting for ongoing treatment discussions and future label or guideline considerations.